Elicio Therapeutics, Inc. cash flow to debt ratio of -254.63% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Elicio Therapeutics, Inc.'s free cash flow has increased 0.50% from $-37.16M last year to $-36.97M, signaling increasing performance

Elicio Therapeutics, Inc.'s debt to equity ratio is 1.78, which means that the company's assets are unhealthy financed, signaling financial risk.

Elicio Therapeutics, Inc.'s debt has increased relative to shareholder equity from -2.30 last year to 1.78 today, signaling weakened financials

Elicio Therapeutics, Inc. has a net cash position, so leverage is healthy.

Elicio Therapeutics, Inc.'s interest coverage ratio is -24.00, which means that the company struggles to meet interest obligations, signaling financial risk.

Elicio Therapeutics, Inc. has insufficient data to evaluate this check.

Elicio Therapeutics, Inc.'s short-term assets of $19.31M exceed its short-term liabilities of $8.11M

Elicio Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Elicio Therapeutics, Inc.'s return on equity of -1.27K%, is lower than 15.00%, indicating bad performance

Elicio Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Elicio Therapeutics, Inc. has insufficient public price history to evaluate earnings stability.

Elicio Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Elicio Therapeutics, Inc. has negative free cash flow, indicating cash burn

Elicio Therapeutics, Inc.'s yearly earnings has increased 23.75% since last year from $-51.90M to $-39.57M, signaling increasing performance

Elicio Therapeutics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -163.43% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Elicio Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Elicio Therapeutics, Inc. has insufficient public price history to evaluate revenue consistency.

Elicio Therapeutics, Inc. has insufficient public price history to evaluate ROE consistency.

Elicio Therapeutics, Inc. has insufficient data to evaluate this check.

Elicio Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Elicio Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on Base EBITDA Valuation model

Elicio Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Elicio Therapeutics, Inc. has insufficient data to evaluate this check.

Elicio Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Elicio Therapeutics, Inc. has a price-to-book ratio of 4.46x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Elicio Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue